Exact Mass: 317.2117

Exact Mass Matches: 317.2117

Found 394 metabolites which its exact mass value is equals to given mass value 317.2117, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Lycorenin

(5aR,7S,11bS,11cS)-9,10-dimethoxy-1-methyl-3,5,5a,7,11b,11c-hexahydro-2H-isochromeno[3,4-g]indol-7-ol

C18H23NO4 (317.1627)


Lycorenine is an alkaloid. Lycorenine is a natural product found in Lycoris radiata, Narcissus munozii-garmendiae, and Hymenocallis littoralis with data available.

   

Nateglinide

(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid

C19H27NO3 (317.1991)


Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naive to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83\\%) and feces (10\\%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound. C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents

   

HEXOCYCLIUM

HEXOCYCLIUM

C20H33N2O+ (317.2593)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   

Butenafine

N-4-Tert-butylbenzyl-N-methyl-1-naphthalene methylamine hydrochloride

C23H27N (317.2143)


Butenafine is only found in individuals that have used or taken this drug. It is a synthetic benzylamine antifungal agent.Although the mechanism of action has not been fully established, it has been suggested that butenafine, like allylamines, interferes with sterol biosynthesis (especially ergosterol) by inhibiting squalene monooxygenase, an enzyme responsible for converting squalene to 2,3-oxydo squalene. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Blockage of squalene monooxygenase also leads to a subsequent accumulation of squalene. When a high concentration of squalene is reached, it is thought to have an effect of directly kill fungal cells. D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

   

Amaryllisine

Amaryllisine

C18H23NO4 (317.1627)


An isoquinoline alkaloid that is 3,4,4a,5,6,10b-hexahydro-5,10b-ethanophenanthridin-9-ol bearing three additional methoxy substituents at positions 3, 7 and 8.

   

Haplophyllidine

Haplophyllidine

C18H23NO4 (317.1627)


Origin: Plant; SubCategory_DNP: Alkaloids derived from anthranilic acid, Quinoline alkaloids

   

Tetrabenazine

9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one

C19H27NO3 (317.1991)


A drug formerly used as an antipsychotic but now used primarily in the treatment of various movement disorders including tardive dyskinesia. Tetrabenazine blocks uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system. [PubChem] D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators N - Nervous system Same as: D08575

   

protoemetine

Ipecac (Protoemetine)

C19H27NO3 (317.1991)


   
   

LY382884

(3S,4aR,6S,8aR)-6-[(4-carboxyphenyl)methyl]-decahydroisoquinoline-3-carboxylic acid

C18H23NO4 (317.1627)


   

Pitrazepin

Pitrazepin

C19H19N5 (317.164)


   

4-Nitroestradiol

4-Nitroestra-1,3,5(10)-triene-3,17beta-diol

C18H23NO4 (317.1627)


   

2-Nitroestradiol

2-Nitroestra-1,3,5(10)-triene-3,17beta-diol; 2-Nitroestradiol

C18H23NO4 (317.1627)


   

MLS002608010

17beta-Hydroxy-4,17-dimethyl-4-azaandrost-5-en-3-one

C20H31NO2 (317.2355)


   

Glycopyrrolate

Glycopyrrolate

C19H27NO3 (317.1991)


   

Cocaethylene

Ethyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid

C18H23NO4 (317.1627)


Cocaethylene is a recreational drug with stimulant, euphoriant, anorectic, sympathomimetic and local anesthetic properties. Three monoamine neurotransmitters known as serotonin (5-HT), norepinephrine (NE), and dopamine (DA) play an important role in cocaethylenes action. Cocaethylene increases the level of serotonergic, noradrenergic, and dopaminergic neurotransmission by inhibiting the action of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) which makes cocaethylene a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).[Note 1]; Normally cocaines metabolism produces two major and biologically inactive metabolites, benzoylecogonine and ecgonine methyl ester. Carboxylesterase is an important part of cocaines metabolism because it acts as the catalyst for the hydrolysis of cocaine which produces the inactive metabolites. If ethanol is present during the metabolism of cocaine, a portion of the cocaine undergoes transesterification with ethanol, instead of undergoing hydrolysis with water, which results in cocaethylene.

   

Pandamarilactonine A

3-methyl-5-(1-{4-[(2Z)-4-methyl-5-oxo-2,5-dihydrofuran-2-ylidene]butyl}pyrrolidin-2-yl)-2,5-dihydrofuran-2-one

C18H23NO4 (317.1627)


Pandamarilactonine D is an alkaloid from Pandanus amaryllifolius. Pandamarilactonine D is a food flavouring. Alkaloid from Pandanus amaryllifolius. Food flavouring

   

Leucyl-Tryptophan

2-[(2-amino-1-hydroxy-4-methylpentylidene)amino]-3-(1H-indol-3-yl)propanoic acid

C17H23N3O3 (317.1739)


Leucyl-Tryptophan is a dipeptide composed of leucine and tryptophan. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Pandamarilactone 1

3-methyl-6-{4-[(2Z)-4-methyl-5-oxo-2,5-dihydrofuran-2-ylidene]butyl}-1-oxa-6-azaspiro[4.5]dec-3-en-2-one

C18H23NO4 (317.1627)


Pandamarilactone 1 is an alkaloid from leaves of Pandanus amaryllifolius. Pandamarilactone 1 is a food flavouring. Alkaloid from leaves of Pandanus amaryllifolius. Food flavouring

   

Pandanamine

(5Z)-3-methyl-5-[4-({4-[(2Z)-4-methyl-5-oxo-2,5-dihydrofuran-2-ylidene]butyl}amino)butylidene]-2,5-dihydrofuran-2-one

C18H23NO4 (317.1627)


Pandanamine is a food flavouring. Pandanamine is an alkaloid from Pandanus amaryllifoliu Food flavouring. Alkaloid from Pandanus amaryllifolius

   

Tryptophyl-Isoleucine

2-{[2-amino-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino}-3-methylpentanoate

C17H23N3O3 (317.1739)


Tryptophyl-Isoleucine is a dipeptide composed of tryptophan and isoleucine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Isoleucyl-Tryptophan

2-[(2-Amino-1-hydroxy-3-methylpentylidene)amino]-3-(1H-indol-3-yl)propanoate

C17H23N3O3 (317.1739)


Isoleucyl-Tryptophan is a dipeptide composed of isoleucine and tryptophan. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Arbutamine

4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol

C18H23NO4 (317.1627)


Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately. C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents

   

Tryptophyl-Leucine

2-{[2-amino-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino}-4-methylpentanoic acid

C17H23N3O3 (317.1739)


Tryptophyl-Leucine is a dipeptide composed of tryptophan and leucine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

alpha-oxycodol

(1S,13R,14S,17S)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-triene-14,17-diol

C18H23NO4 (317.1627)


alpha-oxycodol is a metabolite of oxymorphone. Oxymorphone (Opana, Numorphan, Numorphone) or 14-Hydroxydihydromorphinone is a powerful semi-synthetic opioid analgesic first developed in Germany in 1914, patented in the USA by Endo Pharmaceuticals in 1955 and introduced to the United States market in January 1959 and other countries around the same time. It (along with hydromorphone) was designed to have less incidence of side effects than morphine and heroin. (Wikipedia)

   

beta-oxycodol

(1S,13R,14R,17S)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-triene-14,17-diol

C18H23NO4 (317.1627)


beta-oxycodol is a metabolite of oxymorphone. Oxymorphone (Opana, Numorphan, Numorphone) or 14-Hydroxydihydromorphinone is a powerful semi-synthetic opioid analgesic first developed in Germany in 1914, patented in the USA by Endo Pharmaceuticals in 1955 and introduced to the United States market in January 1959 and other countries around the same time. It (along with hydromorphone) was designed to have less incidence of side effects than morphine and heroin. (Wikipedia)

   

3-hydroxynonanoyl carnitine

3-[(3-hydroxynonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO5 (317.2202)


3-Hydroxynonanoyl carnitine is an acylcarnitine. More specifically, it is an 3-hydroxynonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxynonanoyl carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxynonanoyl carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Suberoyl-L-carnitine

4-[(7-Carboxyheptanoyl)oxy]-4-(trimethylammonio)butanoic acid

C15H27NO6 (317.1838)


Suberoyl-L-carnitine is an acylcarnitine. More specifically, it is an suberoic aicd ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Suberoyl-L-carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Suberoyl-L-carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-methylheptanedioylcarnitine

3-[(6-carboxy-3-methylhexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


3-methylheptanedioylcarnitine is an acylcarnitine. More specifically, it is an 3-methylheptanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-methylheptanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-methylheptanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2,4-dimethylhexanedioylcarnitine

3-[(5-carboxy-3,5-dimethylpentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


2,4-dimethylhexanedioylcarnitine is an acylcarnitine. More specifically, it is an 2,4-dimethylhexanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2,4-dimethylhexanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2,4-dimethylhexanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Octanedioylcarnitine

3-[(7-carboxyheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


Octanedioylcarnitine is an acylcarnitine. More specifically, it is an octanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular octanedioylcarnitine is elevated in the blood or plasma of individuals with pulmonary arterial hypertension (PMID: 32108049) and type 2 diabetes mellitus (PMID: 19369366). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Denopamine

4-(2-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-1-hydroxyethyl)phenol

C18H23NO4 (317.1627)


   

2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate

2-(Morpholin-4-yl)ethyl 1-phenylcyclohexane-1-carboxylic acid

C19H27NO3 (317.1991)


   
   
   

N-Methylpreskimmianine

N-Methylpreskimmianine

C18H23NO4 (317.1627)


   
   

Acetyllobscurinol

Acetyllobscurinol

C19H27NO3 (317.1991)


   

Isostemonamine

Isostemonamine

C18H23NO4 (317.1627)


   
   

Dihydroperfaminole

Dihydroperfaminole

C18H23NO4 (317.1627)


   

O-Methylacutifolin

(-)-O-Methylacutifolin

C18H23NO4 (317.1627)


   

Pandamarilactone 2

Pandamarilactone 2

C18H23NO4 (317.1627)


   
   

drofenine

drofenine

C20H31NO2 (317.2355)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   
   

Tetradecyl sodium sulfate

Tetradecyl sodium sulfate

C14H30NaO4S+ (317.1762)


   

Ac-(E)-6-[2-(1-Hydroxybutyl)-4-methylphenyl]-5-hexenamide

Ac-(E)-6-[2-(1-Hydroxybutyl)-4-methylphenyl]-5-hexenamide

C19H27NO3 (317.1991)


   

8-(3-Methyl-2,5-dihydro-2-oxofuran-5-yl)-3-methyl-2,3,5,6,7,9a-hexahydrospiro[1H-pyrrolo[1,2-a]azepine-9(8H),5(2H)-furan]-2-one

8-(3-Methyl-2,5-dihydro-2-oxofuran-5-yl)-3-methyl-2,3,5,6,7,9a-hexahydrospiro[1H-pyrrolo[1,2-a]azepine-9(8H),5(2H)-furan]-2-one

C18H23NO4 (317.1627)


   
   
   
   

(-)-2-oxy-indolactam V

(-)-2-oxy-indolactam V

C17H23N3O3 (317.1739)


   
   

glaciapyrrole B

glaciapyrrole B

C19H27NO3 (317.1991)


   

(-)-7,11b-dimethoxy-3,3-dimethyl-(4ar,11bc)-2,3,4a,5,6,11b-hexahydro-1H-furo[2,3-b]pyrano[2,3-h]quinoline|Anhydroperforin|anhydroperforine

(-)-7,11b-dimethoxy-3,3-dimethyl-(4ar,11bc)-2,3,4a,5,6,11b-hexahydro-1H-furo[2,3-b]pyrano[2,3-h]quinoline|Anhydroperforin|anhydroperforine

C18H23NO4 (317.1627)


   

Selaginoidine

Selaginoidine

C18H23NO4 (317.1627)


   

methyl 4-Amino-6-[(1R,2S,4aR,8aR)-1,2,4a,5,6,7, 8,8a-octahydro-2-methylnaphthalen-1-yl]-2-oxo-2H-pyran-3-carboxylate|solanapyrone N

methyl 4-Amino-6-[(1R,2S,4aR,8aR)-1,2,4a,5,6,7, 8,8a-octahydro-2-methylnaphthalen-1-yl]-2-oxo-2H-pyran-3-carboxylate|solanapyrone N

C18H23NO4 (317.1627)


   

(6R)-3α-phenylacetoxy-6beta-acetoxytropane|6beta-acetoxy-3alpha-phenylacetoxytropane|Tropane 3alpha,6beta-diol 3-phenylacetate 6-acetate|tropane-3alpha,6beta-diol 3-phenylacetate 6-acetate

(6R)-3α-phenylacetoxy-6beta-acetoxytropane|6beta-acetoxy-3alpha-phenylacetoxytropane|Tropane 3alpha,6beta-diol 3-phenylacetate 6-acetate|tropane-3alpha,6beta-diol 3-phenylacetate 6-acetate

C18H23NO4 (317.1627)


   

SCHEMBL12006860

SCHEMBL12006860

C18H23NO4 (317.1627)


   
   

9,10-dimethoxy-1-methyl-6,7-seco-lycoran-4(12)-en-7-al

9,10-dimethoxy-1-methyl-6,7-seco-lycoran-4(12)-en-7-al

C18H23NO4 (317.1627)


   

C1=CC=C2C3=CC=C4OC(CCC=C(C)C)(C)C=CC4=C3NC2=C1

C1=CC=C2C3=CC=C4OC(CCC=C(C)C)(C)C=CC4=C3NC2=C1

C22H23NO (317.178)


   

4,6,8-trimethoxy-1-methyl-3-(3-methyl-but-2-enyl)-1H-quinolin-2-one|4,6,8-trimethoxy-N-methyl-3-(3-methylbut-2-enyl)-2-quinolone

4,6,8-trimethoxy-1-methyl-3-(3-methyl-but-2-enyl)-1H-quinolin-2-one|4,6,8-trimethoxy-N-methyl-3-(3-methylbut-2-enyl)-2-quinolone

C18H23NO4 (317.1627)


   

3-acetoxy-6-phenylacetoxytropane

3-acetoxy-6-phenylacetoxytropane

C18H23NO4 (317.1627)


   

1-(1,2,3,4,5,6,7,10-octahydro-4,4,10-trimethyl-8H-benzo[e]indol-2-yl)-3-hydroxy-3-methylbutan-2-one|chamobtusin A

1-(1,2,3,4,5,6,7,10-octahydro-4,4,10-trimethyl-8H-benzo[e]indol-2-yl)-3-hydroxy-3-methylbutan-2-one|chamobtusin A

C20H31NO2 (317.2355)


   

9-O-demethyl-7-O-methyllycorenine

9-O-demethyl-7-O-methyllycorenine

C18H23NO4 (317.1627)


   

dihydroferuloyltyramine

dihydroferuloyltyramine

C18H23NO4 (317.1627)


   
   

nortropane-3alpha,7beta-diol 7-benzoate 3-(2-methylpropanoate)

nortropane-3alpha,7beta-diol 7-benzoate 3-(2-methylpropanoate)

C18H23NO4 (317.1627)


   

(7aS,11aS,11bS)-7,7a,8,9,10,11,11a,11b-octahydro-11b-hydroxy-alpha,alpha,8,8,11a-pentamethyl-6H-naphth[1,2-d]azepine-4-methanol|triptotin J

(7aS,11aS,11bS)-7,7a,8,9,10,11,11a,11b-octahydro-11b-hydroxy-alpha,alpha,8,8,11a-pentamethyl-6H-naphth[1,2-d]azepine-4-methanol|triptotin J

C20H31NO2 (317.2355)


   
   

3alpha-Tropanyl 3-hydroxy-4-methoxycinnamate

3alpha-Tropanyl 3-hydroxy-4-methoxycinnamate

C18H23NO4 (317.1627)


   

4,5-Dihydro-2-methoxy-piperin|4,5-Dihydro-Wisanine|4,5-Dihydrowisanin|Deltaalpha,beta-Dihydrowasanin|Deltaalphabeta-dihydrowisanine|N-piperidyl-5-(2-methoxy-4,5-methylenedioxyphenyl)-2-pentenamide

4,5-Dihydro-2-methoxy-piperin|4,5-Dihydro-Wisanine|4,5-Dihydrowisanin|Deltaalpha,beta-Dihydrowasanin|Deltaalphabeta-dihydrowisanine|N-piperidyl-5-(2-methoxy-4,5-methylenedioxyphenyl)-2-pentenamide

C18H23NO4 (317.1627)


   

(2E,4E)-N-[(4-hydroxy-3-methoxyphenyl)ethyl]-2,4-decadienamide

(2E,4E)-N-[(4-hydroxy-3-methoxyphenyl)ethyl]-2,4-decadienamide

C19H27NO3 (317.1991)


A natural product found in Piper boehmeriaefolium.

   

batzellaside B

batzellaside B

C17H35NO4 (317.2566)


   
   

1-NAPHTHYL PP1

1-(tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

C19H19N5 (317.164)


   
   
   
   
   

glycylasparagyllysine

glycylasparagyllysine

C12H23N5O5 (317.1699)


   
   
   
   
   
   
   
   

asparagylglycyllysine

asparagylglycyllysine

C12H23N5O5 (317.1699)


   
   
   
   

Nateglinide

Nateglinide (Starlix)

C19H27NO3 (317.1991)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3289

   

C18H23NO4_1H-Pyrrolo[3,2,1-de]phenanthridin-1-ol, 2,4,5,7,11b,11c-hexahydro-2,9,10-trimethoxy-, (1S,2S,11bS,11cS)

NCGC00384634-01_C18H23NO4_1H-Pyrrolo[3,2,1-de]phenanthridin-1-ol, 2,4,5,7,11b,11c-hexahydro-2,9,10-trimethoxy-, (1S,2S,11bS,11cS)-

C18H23NO4 (317.1627)


   

C18H23NO4_Furo[2,3-b]quinolin-7-ol, 5,6,7,8-tetrahydro-4,8-dimethoxy-8-(3-methyl-2-buten-1-yl)

NCGC00385071-01_C18H23NO4_Furo[2,3-b]quinolin-7-ol, 5,6,7,8-tetrahydro-4,8-dimethoxy-8-(3-methyl-2-buten-1-yl)-

C18H23NO4 (317.1627)


   

Cocaethylene

Cocaethylene

C18H23NO4 (317.1627)


D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018765 - Dopamine Uptake Inhibitors D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D049990 - Membrane Transport Modulators

   

Gly Gly Gly Lys

(2S)-6-amino-2-{2-[2-(2-aminoacetamido)acetamido]acetamido}hexanoic acid

C12H23N5O5 (317.1699)


   

Gly Gly Lys Gly

2-[(2S)-6-amino-2-[2-(2-aminoacetamido)acetamido]hexanamido]acetic acid

C12H23N5O5 (317.1699)


   

Gly Lys Gly Gly

2-{2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]acetamido}acetic acid

C12H23N5O5 (317.1699)


   
   
   
   

Lys Gly Gly Gly

2-(2-{2-[(2S)-2,6-diaminohexanamido]acetamido}acetamido)acetic acid

C12H23N5O5 (317.1699)


   
   
   
   
   
   
   
   
   
   
   
   
   

Trihexyphenidyl N-oxide

Trihexyphenidyl N-oxide

C20H31NO2 (317.2355)


   

Hydroxytrihexyphenidyl

Hydroxytrihexyphenidyl

C20H31NO2 (317.2355)


   

Methscopolamine

Methscopolamine

C18H23NO4 (317.1627)


   

Arbutamine

4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol

C18H23NO4 (317.1627)


C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents

   

Ile-TRP

2-[2-amino-3-(1H-indol-3-yl)propanamido]-3-methylpentanoic acid

C17H23N3O3 (317.1739)


A dipeptide formed from L-isoleucine and L-tryptophan residues.

   

Leu-TRP

2-[2-amino-3-(1H-indol-3-yl)propanamido]-4-methylpentanoic acid

C17H23N3O3 (317.1739)


A dipeptide formed from L-leucine and L-tryptophan residues.

   

TRP-Ile

2-(2-amino-3-methylpentanamido)-3-(1H-indol-3-yl)propanoic acid

C17H23N3O3 (317.1739)


   

TRP-Leu

2-(2-amino-4-methylpentanamido)-3-(1H-indol-3-yl)propanoic acid

C17H23N3O3 (317.1739)


A dipeptide formed from L-tryptophan and L-leucine residues.

   

Pandamarilactonine A

3-methyl-5-(1-{4-[(2Z)-4-methyl-5-oxo-2,5-dihydrofuran-2-ylidene]butyl}pyrrolidin-2-yl)-2,5-dihydrofuran-2-one

C18H23NO4 (317.1627)


   

Pandanamine

(5Z)-3-methyl-5-[4-({4-[(2Z)-4-methyl-5-oxo-2,5-dihydrofuran-2-ylidene]butyl}amino)butylidene]-2,5-dihydrofuran-2-one

C18H23NO4 (317.1627)


   

Pandamarilactone 1

3-methyl-6-{4-[(2Z)-4-methyl-5-oxo-2,5-dihydrofuran-2-ylidene]butyl}-1-oxa-6-azaspiro[4.5]dec-3-en-2-one

C18H23NO4 (317.1627)


   

Homocaine

ethyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate

C18H23NO4 (317.1627)


   
   

1-NA-PP1

1-NAPHTHYL PP1

C19H19N5 (317.164)


   
   

4-Aza-5a-androstan-1-ene-3-one-17b-carboxylic acid

4-Aza-5a-androstan-1-ene-3-one-17b-carboxylic acid

C19H27NO3 (317.1991)


   

4-(Morpholine-4-carbonyl)phenylboronic Acid Pinacol Ester

4-(Morpholine-4-carbonyl)phenylboronic Acid Pinacol Ester

C17H24BNO4 (317.1798)


   

4-METHYL-3-PYRROLIDIN-1-YLMETHYL-PIPERAZINE-1-CARBOXYLICACIDBENZYLESTER

4-METHYL-3-PYRROLIDIN-1-YLMETHYL-PIPERAZINE-1-CARBOXYLICACIDBENZYLESTER

C18H27N3O2 (317.2103)


   

methyl 4-{[(benzyloxy)carbonyl]amino}bicyclo[2.2.2]octane-1-carboxylate

methyl 4-{[(benzyloxy)carbonyl]amino}bicyclo[2.2.2]octane-1-carboxylate

C18H23NO4 (317.1627)


   

6-(DIMETHOXYMETHYL)-3-METHYL-3H-IMIDAZO[4,5-B]PYRIDINE

6-(DIMETHOXYMETHYL)-3-METHYL-3H-IMIDAZO[4,5-B]PYRIDINE

C16H24BNO3Si (317.1618)


   

BENZYL-[2-(4-BENZYLOXY-PHENYL)-ETHYL]-AMINE

BENZYL-[2-(4-BENZYLOXY-PHENYL)-ETHYL]-AMINE

C22H23NO (317.178)


   

4-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)MORPHOLINE

4-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)MORPHOLINE

C18H28BNO3 (317.2162)


   

1-ETHYL-4-(5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE

1-ETHYL-4-(5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE

C17H28BN3O2 (317.2274)


   

N-cyclohexyl-2-nitro-4-((piperidin-1-yl)methyl)benzenamine

N-cyclohexyl-2-nitro-4-((piperidin-1-yl)methyl)benzenamine

C18H27N3O2 (317.2103)


   

1-Benzyl 3-methyl 3-allyl-1,3-piperidinedicarboxylate

1-Benzyl 3-methyl 3-allyl-1,3-piperidinedicarboxylate

C18H23NO4 (317.1627)


   

(4-BENZYLOXYBENZYL)-(1-PHENYL-ETHYL)AMINE

(4-BENZYLOXYBENZYL)-(1-PHENYL-ETHYL)AMINE

C22H23NO (317.178)


   

MORPHOLINO(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)METHANONE

MORPHOLINO(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)METHANONE

C17H24BNO4 (317.1798)


   

N,N-diethyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

N,N-diethyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

C18H28BNO3 (317.2162)


   

N-tert-Butyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

N-tert-Butyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

C18H28BNO3 (317.2162)


   

4-CYANO-3-FLUOROPHENYL TRANS-4-PENTYLCYCLOHEXANECARBOXYLATE

4-CYANO-3-FLUOROPHENYL TRANS-4-PENTYLCYCLOHEXANECARBOXYLATE

C19H24FNO2 (317.1791)


   

N-(2-Methoxyphenyl)-2-(di-t-butylphosphino)pyrrole

N-(2-Methoxyphenyl)-2-(di-t-butylphosphino)pyrrole

C19H28NOP (317.1908)


   

Dicyclohexyl(4-(N,N-dimethylamino)phenyl)phosphine

Dicyclohexyl(4-(N,N-dimethylamino)phenyl)phosphine

C20H32NP (317.2272)


   

DI-TERT-BUTYL 1H-INDOLE-1,5-DICARBOXYLATE

DI-TERT-BUTYL 1H-INDOLE-1,5-DICARBOXYLATE

C18H23NO4 (317.1627)


   

Sodium hydroxytetradecane sulfonate

Sodium hydroxytetradecane sulfonate

C14H30NaO4S (317.1762)


   

Bis(2,4-dimethoxybenzyl)amine

Bis(2,4-dimethoxybenzyl)amine

C18H23NO4 (317.1627)


   

3-(2,5-dimethylphenyl)-3-hydroxy-8-methoxy-1-azaspiro[4.5]decane-2,4-dione

3-(2,5-dimethylphenyl)-3-hydroxy-8-methoxy-1-azaspiro[4.5]decane-2,4-dione

C18H23NO4 (317.1627)


   

tert-butyl N-[1-(2-cyanoethylamino)-1-oxo-3-phenylpropan-2-yl]carbamate

tert-butyl N-[1-(2-cyanoethylamino)-1-oxo-3-phenylpropan-2-yl]carbamate

C17H23N3O3 (317.1739)


   

methyl methyl undecylidene aminobenzoate

methyl methyl undecylidene aminobenzoate

C20H31NO2 (317.2355)


   

(±)-Tetrabenazine

(±)-Tetrabenazine

C19H27NO3 (317.1991)


   

N,N-DIETHYL-2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETAMIDE

N,N-DIETHYL-2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETAMIDE

C18H28BNO3 (317.2162)


   
   

(4aR,4bS,6aS,7S,9aS,9bS)-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid

(4aR,4bS,6aS,7S,9aS,9bS)-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid

C19H27NO3 (317.1991)


   

tert-Butyl 4-oxospiro[chroman-2,4-piperidine]-1-carboxylate

tert-Butyl 4-oxospiro[chroman-2,4-piperidine]-1-carboxylate

C18H23NO4 (317.1627)


   

4-(2-OXO-2,3-DIHYDRO-1H-BENZIMIDAZOL-1-YL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER

4-(2-OXO-2,3-DIHYDRO-1H-BENZIMIDAZOL-1-YL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER

C17H23N3O3 (317.1739)


   

1-(2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOXY)ETHYL)PYRROLIDINE

1-(2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOXY)ETHYL)PYRROLIDINE

C18H28BNO3 (317.2162)


   

ETHYL 3-(3-(2-ETHOXY-2-OXOETHYL)-1-METHYL-1H-INDOL-2-YL)PROPANOATE

ETHYL 3-(3-(2-ETHOXY-2-OXOETHYL)-1-METHYL-1H-INDOL-2-YL)PROPANOATE

C18H23NO4 (317.1627)


   

4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)Morpholine

4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)Morpholine

C18H28BNO3 (317.2162)


   

2-[(4-phenylpiperidin-1-yl)methyl]quinolin-6-amine

2-[(4-phenylpiperidin-1-yl)methyl]quinolin-6-amine

C21H23N3 (317.1892)


   

Denopamine

Denopamine

C18H23NO4 (317.1627)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents Denopamine ((R)-(-)-Denopamine) is an orally active, selective β1-adrenergic agonist. Denopamine prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart. Cardiovascular effects[1].

   

(3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one

(3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one

C19H27NO3 (317.1991)


N - Nervous system

   

2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate

2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate

C19H27NO3 (317.1991)


   

3-methyl-5-[4-[2-(4-methyl-5-oxo-2H-furan-2-yl)pyrrolidin-1-yl]butylidene]furan-2-one

(5Z)-3-methyl-5-[4-[2-(4-methyl-5-oxo-2H-furan-2-yl)pyrrolidin-1-yl]butylidene]furan-2-one

C18H23NO4 (317.1627)


   

(L)-Suberyl Carnitine

(3R)-3-[(7-Carboxyheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


   

(3S,11bS)-tetrabenazine

(3S,11bS)-tetrabenazine

C19H27NO3 (317.1991)


D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators C471 - Enzyme Inhibitor

   

Terodiline hydrochloride

Terodiline hydrochloride

C20H28ClN (317.191)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

Isoleucyl-Tryptophan

Isoleucyl-Tryptophan

C17H23N3O3 (317.1739)


BNC210 (H-Ile-Trp-OH) is an orally active α7 nAChR negative alteration modulator (NAM) with no apparent side effects. BNC210 exhibits acute anxiolytic activity in rodent models of anxiety. BNC210 can be used in studies of generalised anxiety disorders[1].

   

2-{[4-(Methylethyl)cyclohexyl]carbonylamino}-3-phenylpropanoic acid

2-{[4-(Methylethyl)cyclohexyl]carbonylamino}-3-phenylpropanoic acid

C19H27NO3 (317.1991)


   
   

(3S,4aR,6S,8aR)-6-[(4-carboxyphenyl)methyl]-decahydroisoquinoline-3-carboxylic acid

(3S,4aR,6S,8aR)-6-[(4-carboxyphenyl)methyl]-decahydroisoquinoline-3-carboxylic acid

C18H23NO4 (317.1627)


   

2-Nitroestra-1,3,5(10)-triene-3,17beta-diol

2-Nitroestra-1,3,5(10)-triene-3,17beta-diol

C18H23NO4 (317.1627)


   

ent-Nateglinide

ent-Nateglinide

C19H27NO3 (317.1991)


   

Alverine hydrochloride

Alverine hydrochloride

C20H28ClN (317.191)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

(E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one

(E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one

C22H23NO (317.178)


   

N-biphenyl-2-yl-N-(4,6-dimethylpyrimidin-2-yl)guanidine

N-biphenyl-2-yl-N-(4,6-dimethylpyrimidin-2-yl)guanidine

C19H19N5 (317.164)


   

4-Nitroestra-1,3,5(10)-triene-3,17beta-diol

4-Nitroestra-1,3,5(10)-triene-3,17beta-diol

C18H23NO4 (317.1627)


   

L-Seryl-L-leucyl-L-valine

L-Seryl-L-leucyl-L-valine

C14H27N3O5 (317.1951)


   

1-Tert-butyl-5-[2-oxo-2-(1-piperidinyl)ethyl]-4-pyrazolo[3,4-d]pyrimidinone

1-Tert-butyl-5-[2-oxo-2-(1-piperidinyl)ethyl]-4-pyrazolo[3,4-d]pyrimidinone

C16H23N5O2 (317.1852)


   

1-Adamantanecarboxylic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester

1-Adamantanecarboxylic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester

C18H23NO4 (317.1627)


   

4,17alpha-Dimethyl-4-aza-5-androsten-17beta-ol-3-one

4,17alpha-Dimethyl-4-aza-5-androsten-17beta-ol-3-one

C20H31NO2 (317.2355)


   

4,8-Dimethoxy-8-(3-methyl-but-2-enyl)-5,6,7,8-tetrahydro-furo[2,3-b]quinolin-7-ol

4,8-Dimethoxy-8-(3-methyl-but-2-enyl)-5,6,7,8-tetrahydro-furo[2,3-b]quinolin-7-ol

C18H23NO4 (317.1627)


   

Austedo

Austedo

C19H27NO3 (317.1991)


C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system

   

1-(Phenylmethyl)cyclopentyl[(1S)-1-formylpentyl]carbamate

1-(Phenylmethyl)cyclopentyl[(1S)-1-formylpentyl]carbamate

C19H27NO3 (317.1991)


   

TETRABENAZINE

TETRABENAZINE

C19H27NO3 (317.1991)


D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators N - Nervous system Same as: D08575

   

ent-7alpha-hydroxykaur-16-en-19-oate

ent-7alpha-hydroxykaur-16-en-19-oate

C20H29O3- (317.2117)


   

18R-hydroxy-eicosapentaenoate

18R-hydroxy-eicosapentaenoate

C20H29O3- (317.2117)


   

epi-leukotriene A4

epi-leukotriene A4

C20H29O3- (317.2117)


   
   

15-oxo-ETE(1-)

15-oxo-ETE(1-)

C20H29O3- (317.2117)


A polyunsaturated oxo fatty acid anion that is the conjugate base of 15-oxo-ETE.

   

(5Z,9E,11Z,14Z)-8-oxoicosa-5,9,11,14-tetraenoate

(5Z,9E,11Z,14Z)-8-oxoicosa-5,9,11,14-tetraenoate

C20H29O3- (317.2117)


   

12-oxo-ETE(1-)

12-oxo-ETE(1-)

C20H29O3- (317.2117)


A oxo fatty acid anion that is the conjugate base of 12-oxo-ETE, obtained by deprotonation of the carboxy group.

   

kauralexin A3

kauralexin A3

C20H29O3- (317.2117)


   

(11S,16S)-ent-kauran-11,16-epoxy-19-oate

(11S,16S)-ent-kauran-11,16-epoxy-19-oate

C20H29O3- (317.2117)


   

(2S,3S,7R)-2,3-diamino-8-(1-carbamoyl-2-iminoimidazolidin-4-yl)-7-hydroxyoctanoate

(2S,3S,7R)-2,3-diamino-8-(1-carbamoyl-2-iminoimidazolidin-4-yl)-7-hydroxyoctanoate

C12H25N6O4+ (317.1937)


   

(8Z,11Z,14Z,17Z)-3-oxo-icosa-8,11,14,17-tetraenoate

(8Z,11Z,14Z,17Z)-3-oxo-icosa-8,11,14,17-tetraenoate

C20H29O3- (317.2117)


   

2-[(11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]acetaldehyde

2-[(11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]acetaldehyde

C19H27NO3 (317.1991)


   

4-[2-[2-(3,4-Dimethoxyphenyl)ethylamino]-1-hydroxyethyl]phenol

4-[2-[2-(3,4-Dimethoxyphenyl)ethylamino]-1-hydroxyethyl]phenol

C18H23NO4 (317.1627)


   

3-methylheptanedioylcarnitine

3-methylheptanedioylcarnitine

C15H27NO6 (317.1838)


   

2,4-dimethylhexanedioylcarnitine

2,4-dimethylhexanedioylcarnitine

C15H27NO6 (317.1838)


   

(4aS,7R,7aR,12bS)-9-methoxy-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7-diol

(4aS,7R,7aR,12bS)-9-methoxy-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7-diol

C18H23NO4 (317.1627)


   

leukotriene A4(1-)

leukotriene A4(1-)

C20H29O3- (317.2117)


The leukotriene anion that is the conjugate base of leukotriene A4 arising from deprotonation of the carboxylic acid group. Major microspecies at pH 7.3.

   

Leu-Val-Ser

Leu-Val-Ser

C14H27N3O5 (317.1951)


A tripeptide composed of L-leucine, L-valine and L-serine joined in sequence by peptide linkages.

   

Aculene B

Aculene B

C19H27NO3 (317.1991)


A carboxylic ester resulting from the formal condensation of the hydroxy group of aculene D with the carboxylic acid group of L-proline. It is a sesquiterpenoid isolated from the fungus Aspergillus aculeatus.

   

5-oxo-ETE(1-)

5-oxo-ETE(1-)

C20H29O3- (317.2117)


A long-chain fatty acid anion that is the conjugate base of 5-oxo-ETE, obtained by deprotonation of the carboxy group.

   

1-(2-Phenylethyl)-3-[(4-propylcyclohexylidene)amino]thiourea

1-(2-Phenylethyl)-3-[(4-propylcyclohexylidene)amino]thiourea

C18H27N3S (317.1926)


   

15(R)-Hepe(1-)

15(R)-Hepe(1-)

C20H29O3- (317.2117)


An icosanoid anion that is the conjugate base of 15(R)-HEPE arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

(5Z,8Z,11Z,14Z,16E)-18-hydroxyicosa-5,8,11,14,16-pentaenoate

(5Z,8Z,11Z,14Z,16E)-18-hydroxyicosa-5,8,11,14,16-pentaenoate

C20H29O3- (317.2117)


   

2-phenyl-N-(2-(pyrrolidin-1-yl)ethyl)quinolin-4-amine

2-phenyl-N-(2-(pyrrolidin-1-yl)ethyl)quinolin-4-amine

C21H23N3 (317.1892)


   

N-(p-octylbenzoyl)-piperidin-4-ol

N-(p-octylbenzoyl)-piperidin-4-ol

C20H31NO2 (317.2355)


   
   

20-Oxoarachidonate

20-Oxoarachidonate

C20H29O3- (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of 20-oxoarachidonic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

eoxin A4(1-)

eoxin A4(1-)

C20H29O3- (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of eoxin A4, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

17(S),18(R)-EETeTr(1-)

17(S),18(R)-EETeTr(1-)

C20H29O3- (317.2117)


A 17,18-EETeTr(1-) in which the epoxy group has (17S,18R)-configuration.

   

11-oxo-ETE(1-)

11-oxo-ETE(1-)

C20H29O3- (317.2117)


A polyunsaturated oxo fatty acid anion that is the conjugate base of 11-oxo-ETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-cycloheptyl-4-(2-oxolanylmethoxy)benzamide

N-cycloheptyl-4-(2-oxolanylmethoxy)benzamide

C19H27NO3 (317.1991)


   

17,18-EETeTr(1-)

17,18-EETeTr(1-)

C20H29O3- (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of 17,18-EETeTr, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoate

(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoate

C20H29O3- (317.2117)


   

(5Z,8Z,11Z,14Z,17Z)-20-hydroxyicosa-5,8,11,14,17-pentaenoate

(5Z,8Z,11Z,14Z,17Z)-20-hydroxyicosa-5,8,11,14,17-pentaenoate

C20H29O3- (317.2117)


   

11(R)-Hepe(1-)

11(R)-Hepe(1-)

C20H29O3- (317.2117)


An icosanoid anion that is the conjugate base of 11(R)-HEPE arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

(5Z,8Z,11Z,14Z,17Z)-19-hydroxyicosa-5,8,11,14,17-pentaenoate

(5Z,8Z,11Z,14Z,17Z)-19-hydroxyicosa-5,8,11,14,17-pentaenoate

C20H29O3- (317.2117)


   

18(S)-Hepe(1-)

18(S)-Hepe(1-)

C20H29O3- (317.2117)


An 18-HEPE(1-) that is the conjugate base of 18(S)-HEPE, arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

15(S)-Hepe(1-)

15(S)-Hepe(1-)

C20H29O3- (317.2117)


A HEPE(1-) that is the conjugate base of 15(S)-HEPE, arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

17(R),18(S)-EETeTr(1-)

17(R),18(S)-EETeTr(1-)

C20H29O3- (317.2117)


A 17,18-EETeTr(1-) in which the epoxy group has (17R,18S)-configuration.

   

N-[2-(1-cyclohexenyl)ethyl]-3-[(4-methylphenyl)methylthio]propanamide

N-[2-(1-cyclohexenyl)ethyl]-3-[(4-methylphenyl)methylthio]propanamide

C19H27NOS (317.1813)


   

3-hydroxy-6,7-dimethyl-2-[(1E,3E)-nona-1,3-dien-1-yl]-6,7-dihydropyrano[2,3-c]pyrrole-4,5-dione

3-hydroxy-6,7-dimethyl-2-[(1E,3E)-nona-1,3-dien-1-yl]-6,7-dihydropyrano[2,3-c]pyrrole-4,5-dione

C18H23NO4 (317.1627)


   

8,9-epoxy-(5Z,11Z,14Z,17Z)-eicosatetraenoate

8,9-epoxy-(5Z,11Z,14Z,17Z)-eicosatetraenoate

C20H29O3- (317.2117)


   

N-benzyl-4-[(2E)-2-benzylidenehydrazinyl]-6-methylpyrimidin-2-amine

N-benzyl-4-[(2E)-2-benzylidenehydrazinyl]-6-methylpyrimidin-2-amine

C19H19N5 (317.164)


   

(5Z)-7-{(2R,3Z)-3-[(2Z,5Z)-undeca-2,5-dien-1-ylidene]oxiran-2-yl}hept-5-enoate

(5Z)-7-{(2R,3Z)-3-[(2Z,5Z)-undeca-2,5-dien-1-ylidene]oxiran-2-yl}hept-5-enoate

C20H29O3- (317.2117)


   

14,15-Epoxy-(5Z,8Z,11Z,17Z)-eicosatetraenoate

14,15-Epoxy-(5Z,8Z,11Z,17Z)-eicosatetraenoate

C20H29O3- (317.2117)


   

(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoate

(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoate

C20H29O3- (317.2117)


   

11,12-epoxy-(5Z,8Z,14Z,17Z)-eicosatetraenoate

11,12-epoxy-(5Z,8Z,14Z,17Z)-eicosatetraenoate

C20H29O3- (317.2117)


   
   
   
   
   
   
   
   
   

(1R,9S,10S,11S)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-12-methyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1R,9S,10S,11S)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-12-methyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C17H23N3O3 (317.1739)


   

(1S,9R,10R,11R)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-12-methyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

(1S,9R,10R,11R)-N-(cyclopropylmethyl)-10-(hydroxymethyl)-12-methyl-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide

C17H23N3O3 (317.1739)


   
   
   
   
   
   
   
   
   
   
   
   
   
   

(5Z,7E,11Z,14Z)-9-oxoicosa-5,7,11,14-tetraenoate

(5Z,7E,11Z,14Z)-9-oxoicosa-5,7,11,14-tetraenoate

C20H29O3- (317.2117)


   

10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]decanoate

10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]decanoate

C16H29O6- (317.1964)


   

(5Z,7E,11Z,14Z,17Z)-9-hydroxyicosa-5,7,11,14,17-pentaenoate

(5Z,7E,11Z,14Z,17Z)-9-hydroxyicosa-5,7,11,14,17-pentaenoate

C20H29O3- (317.2117)


   

(2S)-2,6-bis[(3R)-3-aminobutanamido]hexanoate

(2S)-2,6-bis[(3R)-3-aminobutanamido]hexanoate

C14H29N4O4+ (317.2189)


   

4-Hydroxy-all-trans-13,14-dihydroretinoate

4-Hydroxy-all-trans-13,14-dihydroretinoate

C20H29O3- (317.2117)


   

12(S)-Hepe(1-)

12(S)-Hepe(1-)

C20H29O3- (317.2117)


   

(9R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydecanoate

(9R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydecanoate

C16H29O6- (317.1964)


   

5(S)-Hepe(1-)

5(S)-Hepe(1-)

C20H29O3- (317.2117)


   

(3Z,6Z,9Z,12Z,15Z)-N-(2-hydroxyethyl)octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-(2-hydroxyethyl)octadeca-3,6,9,12,15-pentaenamide

C20H31NO2 (317.2355)


   

N-Benzyl-3-cyclohexaencarbonyloxy-2,2-dimethylpropanamide

N-Benzyl-3-cyclohexaencarbonyloxy-2,2-dimethylpropanamide

C19H27NO3 (317.1991)


   

butenafine

butenafine

C23H27N (317.2143)


D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

   
   

Tryptophylisoleucine

Tryptophylisoleucine

C17H23N3O3 (317.1739)


   

Ethylbenzoylecgonine

Ethylbenzoylecgonine

C18H23NO4 (317.1627)


   

alpha-oxycodol

alpha-oxycodol

C18H23NO4 (317.1627)


   

O-suberoylcarnitine

O-suberoylcarnitine

C15H27NO6 (317.1838)


An O-acylcarnitine having suberoyl (7-carboxyheptanoyl) as the acyl substituent.

   

3-Hydroxynonanoylcarnitine

3-Hydroxynonanoylcarnitine

C16H31NO5 (317.2202)


   

19-HEPE(1-)

19-HEPE(1-)

C20H29O3 (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of 19-HEPE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

pyranonigrin G

pyranonigrin G

C18H23NO4 (317.1627)


A member of the class of pyranopyrroles with formula C18H23NO4, originally isolated from Aspergillus niger.

   

(5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoate

(5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoate

C20H29O3 (317.2117)


An EpETE(1-) that is the conjugate base of (5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5Z,8R,9Z,11Z,14Z)-8,9-epoxyicosatetraenoate

(5Z,8R,9Z,11Z,14Z)-8,9-epoxyicosatetraenoate

C20H29O3 (317.2117)


An EpETE(1-) that is the conjugate base of (5Z,8R,9Z,11Z,14Z)-8,9-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

17beta-Hydroxy-4,17-dimethyl-4-azaandrost-5-en-3-one

17beta-Hydroxy-4,17-dimethyl-4-azaandrost-5-en-3-one

C20H31NO2 (317.2355)


   

(3R)-3-[(7-Carboxyheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

(3R)-3-[(7-Carboxyheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


   

9-HEPE(1-)

9-HEPE(1-)

C20H29O3 (317.2117)


A HEPE(1-) that is the conjugate base of 9-HEPE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#16(1-)

ascr#16(1-)

C16H29O6 (317.1964)


Conjugate base of ascr#16

   

8-oxo-ETE(1-)

8-oxo-ETE(1-)

C20H29O3 (317.2117)


An unsaturated fatty acid anion that is the conjugate base of 8-KETE, obtained by deprotonation of the carboxy group.

   

5-HEPE(1-)

5-HEPE(1-)

C20H29O3 (317.2117)


An icosanoid anion that is the conjugate base of 5-HEPE arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

18(R)-HEPE(1-)

18(R)-HEPE(1-)

C20H29O3 (317.2117)


An icosanoid anion that is the conjugate base of 18(R)-HEPE arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

18-HEPE(1-)

18-HEPE(1-)

C20H29O3 (317.2117)


An icosanoid anion that is the conjugate base of 18-HEPE, arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

oscr#16(1-)

oscr#16(1-)

C16H29O6 (317.1964)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#16, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

20-HEPE(1-)

20-HEPE(1-)

C20H29O3 (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of 20-HEPE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

12-HEPE(1-)

12-HEPE(1-)

C20H29O3 (317.2117)


A HEPE(1-) that is the conjugate base of 12-HEPE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoate

(5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoate

C20H29O3 (317.2117)


An EpETE(1-) that is the conjugate base of (5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5Z,8Z,11Z,17Z)-14,15-Epoxyicosatetraenoate

(5Z,8Z,11Z,17Z)-14,15-Epoxyicosatetraenoate

C20H29O3 (317.2117)


An EpETE(1-) that is the conjugate base of (5Z,8Z,11Z,17Z)-14,15-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   
   
   
   

5,6,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2,4,6,13-tetraen-4-ol

5,6,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2,4,6,13-tetraen-4-ol

C18H23NO4 (317.1627)


   

methyl (1s,16s)-16-methoxy-5-oxa-10-azatetracyclo[8.7.0.0¹,¹³.0²,⁶]heptadeca-2(6),3,13-triene-4-carboxylate

methyl (1s,16s)-16-methoxy-5-oxa-10-azatetracyclo[8.7.0.0¹,¹³.0²,⁶]heptadeca-2(6),3,13-triene-4-carboxylate

C18H23NO4 (317.1627)


   

2-[(6r,7s,7as)-6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl]-4,5-dimethoxybenzaldehyde

2-[(6r,7s,7as)-6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl]-4,5-dimethoxybenzaldehyde

C18H23NO4 (317.1627)


   

kesselringine

kesselringine

C18H23NO4 (317.1627)


   

(2z,4e)-6,7-dihydroxy-3,7,11-trimethyl-1-(1h-pyrrol-2-yl)dodeca-2,4,10-trien-1-one

(2z,4e)-6,7-dihydroxy-3,7,11-trimethyl-1-(1h-pyrrol-2-yl)dodeca-2,4,10-trien-1-one

C19H27NO3 (317.1991)


   

(2e)-5-(6-methoxy-2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)pent-2-en-1-one

(2e)-5-(6-methoxy-2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)pent-2-en-1-one

C18H23NO4 (317.1627)


   

8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-7,12-diol

8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-7,12-diol

C18H23NO4 (317.1627)


   

1-ethyl-3a,6-dimethyl-3-oxo-4,5,8,8a-tetrahydroazulen-4-yl pyrrolidine-2-carboxylate

1-ethyl-3a,6-dimethyl-3-oxo-4,5,8,8a-tetrahydroazulen-4-yl pyrrolidine-2-carboxylate

C19H27NO3 (317.1991)


   

(1s,8r,10r,17s)-4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol

(1s,8r,10r,17s)-4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol

C18H23NO4 (317.1627)


   

(1s,10s,12s)-4-hydroxy-5-methoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate

(1s,10s,12s)-4-hydroxy-5-methoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate

C18H23NO4 (317.1627)


   

3-methoxy-4,4'-dimethyl-10'-azaspiro[furan-2,2'-tricyclo[8.3.0.0¹,⁵]tridecan]-4'-ene-3',5-dione

3-methoxy-4,4'-dimethyl-10'-azaspiro[furan-2,2'-tricyclo[8.3.0.0¹,⁵]tridecan]-4'-ene-3',5-dione

C18H23NO4 (317.1627)


   

2-{3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}acetaldehyde

2-{3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}acetaldehyde

C19H27NO3 (317.1991)


   

(5r)-3-methyl-5-[(2s)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

(5r)-3-methyl-5-[(2s)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

(8s,9as,13as)-4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

(8s,9as,13as)-4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

C19H27NO3 (317.1991)


   

3-(4-hydroxy-3-{[(2e,4e)-1-hydroxy-7-methylocta-2,4-dien-1-ylidene]amino}phenyl)propanoic acid

3-(4-hydroxy-3-{[(2e,4e)-1-hydroxy-7-methylocta-2,4-dien-1-ylidene]amino}phenyl)propanoic acid

C18H23NO4 (317.1627)


   

9-hydroxy-10-(1-hydroxyhexa-2,4-dien-1-ylidene)-7,9-dimethyl-2-azatricyclo[5.2.2.0²,⁶]undecane-8,11-dione

9-hydroxy-10-(1-hydroxyhexa-2,4-dien-1-ylidene)-7,9-dimethyl-2-azatricyclo[5.2.2.0²,⁶]undecane-8,11-dione

C18H23NO4 (317.1627)


   

2,11-dimethoxy-5,5-dimethyl-6,15-dioxa-17-azatetracyclo[8.7.0.0²,⁷.0¹²,¹⁶]heptadeca-1(10),11,13,16-tetraene

2,11-dimethoxy-5,5-dimethyl-6,15-dioxa-17-azatetracyclo[8.7.0.0²,⁷.0¹²,¹⁶]heptadeca-1(10),11,13,16-tetraene

C18H23NO4 (317.1627)


   

13,16-dimethyl-18-(prop-1-en-2-yl)-15-oxa-4-azapentacyclo[14.2.1.0²,¹⁴.0³,¹¹.0⁵,¹⁰]nonadeca-2(14),3(11),5(10),6,8,12-hexaene

13,16-dimethyl-18-(prop-1-en-2-yl)-15-oxa-4-azapentacyclo[14.2.1.0²,¹⁴.0³,¹¹.0⁵,¹⁰]nonadeca-2(14),3(11),5(10),6,8,12-hexaene

C22H23NO (317.178)


   

3-methyl-5-(4-{[4-(4-methyl-5-oxofuran-2-ylidene)butyl]amino}butylidene)furan-2-one

3-methyl-5-(4-{[4-(4-methyl-5-oxofuran-2-ylidene)butyl]amino}butylidene)furan-2-one

C18H23NO4 (317.1627)


   

(1r,8r,10s,17r)-4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol

(1r,8r,10s,17r)-4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol

C18H23NO4 (317.1627)


   

(5s)-3-methyl-5-[(2r)-1-{4-[(2z)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

(5s)-3-methyl-5-[(2r)-1-{4-[(2z)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

3-hydroxy-n-(2-hydroxy-5-oxocyclopent-1-en-1-yl)-8-methyldodeca-4,6,8,10-tetraenimidic acid

3-hydroxy-n-(2-hydroxy-5-oxocyclopent-1-en-1-yl)-8-methyldodeca-4,6,8,10-tetraenimidic acid

C18H23NO4 (317.1627)


   

9,15-dimethoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-triene

9,15-dimethoxy-5,7-dioxa-12-azapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-triene

C18H23NO4 (317.1627)


   

(3ar,4s,8ar)-1-ethyl-3a,6-dimethyl-3-oxo-4,5,8,8a-tetrahydroazulen-4-yl (2s)-pyrrolidine-2-carboxylate

(3ar,4s,8ar)-1-ethyl-3a,6-dimethyl-3-oxo-4,5,8,8a-tetrahydroazulen-4-yl (2s)-pyrrolidine-2-carboxylate

C19H27NO3 (317.1991)


   

4,6,8-trimethoxy-1-methyl-3-(3-methylbut-2-en-1-yl)quinolin-2-one

4,6,8-trimethoxy-1-methyl-3-(3-methylbut-2-en-1-yl)quinolin-2-one

C18H23NO4 (317.1627)


   

(5r)-3-methyl-5-[(2r)-1-{4-[(2z)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

(5r)-3-methyl-5-[(2r)-1-{4-[(2z)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

(1s,10r,12r)-5,6,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2,4,6,13-tetraen-4-ol

(1s,10r,12r)-5,6,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2,4,6,13-tetraen-4-ol

C18H23NO4 (317.1627)


   

methyl 6-[(1r,2s,4ar,8ar)-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-4-amino-2-oxopyran-3-carboxylate

methyl 6-[(1r,2s,4ar,8ar)-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-4-amino-2-oxopyran-3-carboxylate

C18H23NO4 (317.1627)


   

(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-3-(1h-indol-3-yl)propanoic acid

(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-3-(1h-indol-3-yl)propanoic acid

C17H23N3O3 (317.1739)


   

methyl 16-methoxy-5-oxa-10-azatetracyclo[8.7.0.0¹,¹³.0²,⁶]heptadeca-2(6),3,13-triene-4-carboxylate

methyl 16-methoxy-5-oxa-10-azatetracyclo[8.7.0.0¹,¹³.0²,⁶]heptadeca-2(6),3,13-triene-4-carboxylate

C18H23NO4 (317.1627)


   

3,10-dimethyl-3-(3-methylbut-2-en-1-yl)-6h-pyrano[2,3-c]carbazole

3,10-dimethyl-3-(3-methylbut-2-en-1-yl)-6h-pyrano[2,3-c]carbazole

C22H23NO (317.178)


   

(5z)-3-methyl-5-[4-({4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}amino)butylidene]furan-2-one

(5z)-3-methyl-5-[4-({4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}amino)butylidene]furan-2-one

C18H23NO4 (317.1627)


   

4,12-dimethoxy-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,11-tetraene-3,13-diol

4,12-dimethoxy-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,11-tetraene-3,13-diol

C18H23NO4 (317.1627)


   

(2s)-2-{[(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-3-methylbutylidene]amino}-3-hydroxypropanoic acid

(2s)-2-{[(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-3-methylbutylidene]amino}-3-hydroxypropanoic acid

C14H27N3O5 (317.1951)


   

(5s)-3-methyl-5-[(2r)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

(5s)-3-methyl-5-[(2r)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

1-[(2s,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]ethanone

1-[(2s,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]ethanone

C19H27NO3 (317.1991)


   

1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,8h,9h,10h-cyclohepta[d]isoindol-11-one

1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,8h,9h,10h-cyclohepta[d]isoindol-11-one

C20H31NO2 (317.2355)


   

(2s,7r)-2,11-dimethoxy-5,5-dimethyl-6,15-dioxa-17-azatetracyclo[8.7.0.0²,⁷.0¹²,¹⁶]heptadeca-1(10),11,13,16-tetraene

(2s,7r)-2,11-dimethoxy-5,5-dimethyl-6,15-dioxa-17-azatetracyclo[8.7.0.0²,⁷.0¹²,¹⁶]heptadeca-1(10),11,13,16-tetraene

C18H23NO4 (317.1627)


   

6,7-dihydroxy-3,7,11-trimethyl-1-(1h-pyrrol-2-yl)dodeca-2,4,10-trien-1-one

6,7-dihydroxy-3,7,11-trimethyl-1-(1h-pyrrol-2-yl)dodeca-2,4,10-trien-1-one

C19H27NO3 (317.1991)


   

3-methyl-6-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]-1-oxa-6-azaspiro[4.5]dec-3-en-2-one

3-methyl-6-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]-1-oxa-6-azaspiro[4.5]dec-3-en-2-one

C18H23NO4 (317.1627)


   

(4e,6e,8e,10e)-3-hydroxy-n-(2-hydroxy-5-oxocyclopent-1-en-1-yl)-8-methyldodeca-4,6,8,10-tetraenimidic acid

(4e,6e,8e,10e)-3-hydroxy-n-(2-hydroxy-5-oxocyclopent-1-en-1-yl)-8-methyldodeca-4,6,8,10-tetraenimidic acid

C18H23NO4 (317.1627)


   

4,8-dimethoxy-3-[(2s)-2-methoxy-3-methylbut-3-en-1-yl]-1-methylquinolin-2-one

4,8-dimethoxy-3-[(2s)-2-methoxy-3-methylbut-3-en-1-yl]-1-methylquinolin-2-one

C18H23NO4 (317.1627)


   

4,8-dimethoxy-8-(3-methylbut-2-en-1-yl)-5h,6h,7h-furo[2,3-b]quinolin-7-ol

4,8-dimethoxy-8-(3-methylbut-2-en-1-yl)-5h,6h,7h-furo[2,3-b]quinolin-7-ol

C18H23NO4 (317.1627)


   

(5s)-3-methyl-5-[(2r)-1-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]pyrrolidin-2-yl]-5h-furan-2-one

(5s)-3-methyl-5-[(2r)-1-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

(7as,11as,11bs)-4-(2-hydroxypropan-2-yl)-8,8,11a-trimethyl-6h,7h,7ah,9h,10h,11h-naphtho[1,2-d]azepin-11b-ol

(7as,11as,11bs)-4-(2-hydroxypropan-2-yl)-8,8,11a-trimethyl-6h,7h,7ah,9h,10h,11h-naphtho[1,2-d]azepin-11b-ol

C20H31NO2 (317.2355)


   

(5r)-3-methyl-5-[(2s)-1-{4-[(2z)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

(5r)-3-methyl-5-[(2s)-1-{4-[(2z)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4,6,8(15),11-pentaene-2,11-diol

13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4,6,8(15),11-pentaene-2,11-diol

C17H23N3O3 (317.1739)


   

(1s,10s,13s)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4,6,8(15),11-pentaene-2,11-diol

(1s,10s,13s)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4,6,8(15),11-pentaene-2,11-diol

C17H23N3O3 (317.1739)


   

3-[(1s)-4-hydroxy-5-methoxycyclohexa-2,4-dien-1-yl]-n-[2-(4-hydroxyphenyl)ethyl]propanimidic acid

3-[(1s)-4-hydroxy-5-methoxycyclohexa-2,4-dien-1-yl]-n-[2-(4-hydroxyphenyl)ethyl]propanimidic acid

C18H23NO4 (317.1627)


   

4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

C19H27NO3 (317.1991)


   

(9bs,11r,12r)-8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-7,12-diol

(9bs,11r,12r)-8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinoline-7,12-diol

C18H23NO4 (317.1627)


   

(1s,8s,10r,17s)-4,8-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-5-ol

(1s,8s,10r,17s)-4,8-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-5-ol

C18H23NO4 (317.1627)


   

13-methyl-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7,9,17-triene-4,5,8-triol

13-methyl-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7,9,17-triene-4,5,8-triol

C18H23NO4 (317.1627)


   

(1r,12s)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-8-ol

(1r,12s)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-8-ol

C18H23NO4 (317.1627)


   

4,7,8-trimethoxy-1-methyl-3-(3-methylbut-2-en-1-yl)quinolin-2-one

4,7,8-trimethoxy-1-methyl-3-(3-methylbut-2-en-1-yl)quinolin-2-one

C18H23NO4 (317.1627)


   

3-methyl-5-{1-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]pyrrolidin-2-yl}-5h-furan-2-one

3-methyl-5-{1-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]pyrrolidin-2-yl}-5h-furan-2-one

C18H23NO4 (317.1627)


   

4-methyl-8'-(4-methyl-5-oxo-2h-furan-2-yl)-1',2',3',5',6',7',8',9'a-octahydrospiro[furan-2,9'-pyrrolo[1,2-a]azepin]-5-one

4-methyl-8'-(4-methyl-5-oxo-2h-furan-2-yl)-1',2',3',5',6',7',8',9'a-octahydrospiro[furan-2,9'-pyrrolo[1,2-a]azepin]-5-one

C18H23NO4 (317.1627)


   

(1s,14s,15s,16s)-4,5,14-trimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

(1s,14s,15s,16s)-4,5,14-trimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

C18H23NO4 (317.1627)


   

(1r,10s,13s)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4,6,8(15),11-pentaene-2,11-diol

(1r,10s,13s)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-2,4,6,8(15),11-pentaene-2,11-diol

C17H23N3O3 (317.1739)


   

(1r,9s,10s,13r)-4,12-dimethoxy-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,11-tetraene-3,13-diol

(1r,9s,10s,13r)-4,12-dimethoxy-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,11-tetraene-3,13-diol

C18H23NO4 (317.1627)


   

(5r)-3-methyl-5-[(2r)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

(5r)-3-methyl-5-[(2r)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

(1s,5r)-3-(acetyloxy)-8-methyl-8-azabicyclo[3.2.1]octan-6-yl 2-phenylacetate

(1s,5r)-3-(acetyloxy)-8-methyl-8-azabicyclo[3.2.1]octan-6-yl 2-phenylacetate

C18H23NO4 (317.1627)


   

13-methoxy-5-methyl-12-oxa-5-azapentacyclo[11.3.1.1¹,⁴.0²,¹¹.0³,⁸]octadeca-2(11),3(8),9-triene-10,14-diol

13-methoxy-5-methyl-12-oxa-5-azapentacyclo[11.3.1.1¹,⁴.0²,¹¹.0³,⁸]octadeca-2(11),3(8),9-triene-10,14-diol

C18H23NO4 (317.1627)


   

8-methoxy-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7(17),8,10(18)-triene-4,5-diol

8-methoxy-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7(17),8,10(18)-triene-4,5-diol

C18H23NO4 (317.1627)


   

(1s,10r)-10-heptyl-6-methyl-7,9,12-triazatricyclo[6.3.1.0⁴,¹²]dodeca-4,6,8-triene-5-carboxylic acid

(1s,10r)-10-heptyl-6-methyl-7,9,12-triazatricyclo[6.3.1.0⁴,¹²]dodeca-4,6,8-triene-5-carboxylic acid

C18H27N3O2 (317.2103)


   

4-(2-hydroxypropan-2-yl)-8,8,11a-trimethyl-6h,7h,7ah,9h,10h,11h-naphtho[1,2-d]azepin-11b-ol

4-(2-hydroxypropan-2-yl)-8,8,11a-trimethyl-6h,7h,7ah,9h,10h,11h-naphtho[1,2-d]azepin-11b-ol

C20H31NO2 (317.2355)


   

(1s,10r,12s)-4-hydroxy-5-methoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate

(1s,10r,12s)-4-hydroxy-5-methoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate

C18H23NO4 (317.1627)


   

(1r,10s,12s)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-8-ol

(1r,10s,12s)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraen-8-ol

C18H23NO4 (317.1627)


   

4,5,14-trimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

4,5,14-trimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

C18H23NO4 (317.1627)


   

(2r,3s,4s,6s)-2-(hydroxymethyl)-6-(2-hydroxyundecyl)piperidine-3,4-diol

(2r,3s,4s,6s)-2-(hydroxymethyl)-6-(2-hydroxyundecyl)piperidine-3,4-diol

C17H35NO4 (317.2566)


   

(1s,6r,7r,9s)-10-[(2e,4e)-hexa-2,4-dienoyl]-9,11-dihydroxy-7,9-dimethyl-2-azatricyclo[5.2.2.0²,⁶]undec-10-en-8-one

(1s,6r,7r,9s)-10-[(2e,4e)-hexa-2,4-dienoyl]-9,11-dihydroxy-7,9-dimethyl-2-azatricyclo[5.2.2.0²,⁶]undec-10-en-8-one

C18H23NO4 (317.1627)


   

1-{3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}ethanone

1-{3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}ethanone

C19H27NO3 (317.1991)


   

4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol

4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraen-8-ol

C18H23NO4 (317.1627)


   

(2s,8's,9'as)-4-methyl-8'-[(2r)-4-methyl-5-oxo-2h-furan-2-yl]-1',2',3',5',6',7',8',9'a-octahydrospiro[furan-2,9'-pyrrolo[1,2-a]azepin]-5-one

(2s,8's,9'as)-4-methyl-8'-[(2r)-4-methyl-5-oxo-2h-furan-2-yl]-1',2',3',5',6',7',8',9'a-octahydrospiro[furan-2,9'-pyrrolo[1,2-a]azepin]-5-one

C18H23NO4 (317.1627)


   

(5s)-3-methyl-5-[(2s)-1-{4-[(2z)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

(5s)-3-methyl-5-[(2s)-1-{4-[(2z)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

4,8-dimethoxy-3-(2-methoxy-3-methylbut-3-en-1-yl)-1-methylquinolin-2-one

4,8-dimethoxy-3-(2-methoxy-3-methylbut-3-en-1-yl)-1-methylquinolin-2-one

C18H23NO4 (317.1627)


   

1-formyl-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (2s)-3-hydroxy-2-phenylpropanoate

1-formyl-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (2s)-3-hydroxy-2-phenylpropanoate

C18H23NO4 (317.1627)


   

2-(6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl)-4,5-dimethoxybenzaldehyde

2-(6-hydroxy-1-methyl-2,3,5,6,7,7a-hexahydroindol-7-yl)-4,5-dimethoxybenzaldehyde

C18H23NO4 (317.1627)


   

(5r)-3-methyl-5-[(2r)-1-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]pyrrolidin-2-yl]-5h-furan-2-one

(5r)-3-methyl-5-[(2r)-1-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

3-{4-hydroxy-3-[(1-hydroxy-7-methylocta-2,4-dien-1-ylidene)amino]phenyl}propanoic acid

3-{4-hydroxy-3-[(1-hydroxy-7-methylocta-2,4-dien-1-ylidene)amino]phenyl}propanoic acid

C18H23NO4 (317.1627)


   

(5s)-3-methyl-5-[(2s)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

(5s)-3-methyl-5-[(2s)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]-5h-furan-2-one

C18H23NO4 (317.1627)


   

(1r,4r,5r,14r)-8-methoxy-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7(17),8,10(18)-triene-4,5-diol

(1r,4r,5r,14r)-8-methoxy-6-oxa-13-azapentacyclo[8.6.2.1¹,⁵.0⁷,¹⁷.0¹⁴,¹⁸]nonadeca-7(17),8,10(18)-triene-4,5-diol

C18H23NO4 (317.1627)


   

methyl 4-amino-6-(2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)-2-oxopyran-3-carboxylate

methyl 4-amino-6-(2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)-2-oxopyran-3-carboxylate

C18H23NO4 (317.1627)


   

(5r)-3-methyl-6-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}-1-oxa-6-azaspiro[4.5]dec-3-en-2-one

(5r)-3-methyl-6-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}-1-oxa-6-azaspiro[4.5]dec-3-en-2-one

C18H23NO4 (317.1627)


   

(1r,4r,13s,14s)-13-methoxy-5-methyl-12-oxa-5-azapentacyclo[11.3.1.1¹,⁴.0²,¹¹.0³,⁸]octadeca-2(11),3(8),9-triene-10,14-diol

(1r,4r,13s,14s)-13-methoxy-5-methyl-12-oxa-5-azapentacyclo[11.3.1.1¹,⁴.0²,¹¹.0³,⁸]octadeca-2(11),3(8),9-triene-10,14-diol

C18H23NO4 (317.1627)


   

(1r,14r,15r,16r)-4,5,14-trimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

(1r,14r,15r,16r)-4,5,14-trimethoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-ol

C18H23NO4 (317.1627)


   

11'-methoxy-6'-methyl-6'-azaspiro[cyclohexane-1,2'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(12'),9'(13'),10'-triene-4,12'-diol

11'-methoxy-6'-methyl-6'-azaspiro[cyclohexane-1,2'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(12'),9'(13'),10'-triene-4,12'-diol

C19H27NO3 (317.1991)


   

(1s,6r,7r,9s)-9-hydroxy-10-[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]-7,9-dimethyl-2-azatricyclo[5.2.2.0²,⁶]undecane-8,11-dione

(1s,6r,7r,9s)-9-hydroxy-10-[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]-7,9-dimethyl-2-azatricyclo[5.2.2.0²,⁶]undecane-8,11-dione

C18H23NO4 (317.1627)


   

(1'r,2s)-3-methoxy-4,4'-dimethyl-10'-azaspiro[furan-2,2'-tricyclo[8.3.0.0¹,⁵]tridecan]-4'-ene-3',5-dione

(1'r,2s)-3-methoxy-4,4'-dimethyl-10'-azaspiro[furan-2,2'-tricyclo[8.3.0.0¹,⁵]tridecan]-4'-ene-3',5-dione

C18H23NO4 (317.1627)


   

(3s,3ar,4s,6as,8s,11ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,8h,9h,10h-cyclohepta[d]isoindol-11-one

(3s,3ar,4s,6as,8s,11ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,8h,9h,10h-cyclohepta[d]isoindol-11-one

C20H31NO2 (317.2355)


   

5-(6-methoxy-2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)pent-2-en-1-one

5-(6-methoxy-2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)pent-2-en-1-one

C18H23NO4 (317.1627)


   

4-hydroxy-5-methoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate

4-hydroxy-5-methoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5-trien-12-yl acetate

C18H23NO4 (317.1627)


   

(1s,4s,13r,14r)-13-methoxy-5-methyl-12-oxa-5-azapentacyclo[11.3.1.1¹,⁴.0²,¹¹.0³,⁸]octadeca-2(11),3(8),9-triene-10,14-diol

(1s,4s,13r,14r)-13-methoxy-5-methyl-12-oxa-5-azapentacyclo[11.3.1.1¹,⁴.0²,¹¹.0³,⁸]octadeca-2(11),3(8),9-triene-10,14-diol

C18H23NO4 (317.1627)


   

(1'r,2r)-3-methoxy-4,4'-dimethyl-10'-azaspiro[furan-2,2'-tricyclo[8.3.0.0¹,⁵]tridecan]-4'-ene-3',5-dione

(1'r,2r)-3-methoxy-4,4'-dimethyl-10'-azaspiro[furan-2,2'-tricyclo[8.3.0.0¹,⁵]tridecan]-4'-ene-3',5-dione

C18H23NO4 (317.1627)


   

(8r,9ar,13ar)-4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

(8r,9ar,13ar)-4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

C19H27NO3 (317.1991)